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BACKGROUND :
Various problems arise during surgery for Jehovah’s Witnesses
where there is a possibility of a certain amount of bleeding because
these individuals refuse blood transfusions on religious grounds.
The progress of the tumor and general conditions of the patient
influence the indications for bloodless therapy. A Jehovah’s Wit-
ness with advanced esophageal cancer was safely treated by sub-
total esophagectomy following to induction chemotherapy. Here
we reported the perioperative management of this case.
CASE PRESENTATION :
A 50-year-old female presented the chief complaints of anorexia,
weight loss, and dysphagia. She had a history of dysphagia three
months prior to visiting our department. She was diagnosed of ad-
vanced esophageal cancer by upper endoscopy. The patient in-
formed us that she was a Jehovah’s Witness. Blood biochemistry
findings showed decreased hemoglobin of 11.4 g/dL and increaed
levels of squamous cell carcinoma antigen of 3.6 ng/mL (normal
range1.5 mg/mL). Upper endoscopy showed a stricture of the
upper thoracic esophagus, which made passage of the endoscope
difficult (Fig. 1a). The result of a biopsy was diagnosed of squamous
cell carcinoma. Computed tomography (CT) showed thickening of
the esophageal wall in the upper and lower thoracic esophagus
(Fig. 1b, c) and mediastinal lymph node metastasis. Induction
chemotherapy was chosen because we judged it to be resectable
after reduction. Chemotherapy using weekly docetaxel plus low-
dose cisplatin and 5-fluorouracil (1) was started. After starting
chemotherapy, the patient appeared grade 3 leukopenia. After 1
week of rest, chemotherapy was resumed. But she appeared grade
4 leukopenia and grade 3 anemia after chemotherapy. She was
given oral doses of folic acid, vitamin B12 and iron. The tumor of
upper esophagus was found to have completely disappeared on
upper endoscopy (Fig. 2a), whereas the tumor of lower esophagus
had shrunk but still remained. CT scan also showed marked reduc-
tion of the both lesions of the upper and lower thoracic esophagus
(Fig. 2b, c), further showed reduction of lymph nodes. We judged
partial response from their results after induction chemotherapy.
Two weeks prior to surgery, the patient was intramuscular injec-
tion of erythropoietin (6000 U) to increase hemoglobin levels to
11.7 g/dL for surgery (Fig. 3). The attending physician, anesthe-
siologist and the patient signed a liability waiver for blood transfu-
sion refusal before surgery. Although the patient refused blood
products, she approved a preoperative hemodilution, intraopera-
tive blood salvage and postoperative autologous blood transfusion
with salvaged blood. She also approved the use of plasma deriva-
tives.
Intraoperative findings : We rapidly infused a large amount of
Ringer solution and blood substitute after inducing anesthesia,
diluted the blood, and relatively reduced intraoperative bleeding.
The patient’s hemoglobin level was diluted to 8.4 g/dL. We used
intraoperative blood salvage using “Cell Saver”. A total of 200 mL
of blood was collected. We started the thorascopic surgery in the
lateral decubitus position. The tumor in the lower esophagus had
invaded to the aorta, and it was judged unresectable, Non curative
resection was performed. A narrow gastric tube was made and an-
astomosed with hand suture through the retrosternal route. The
operative time was 9 hours 43 minutes and the total amount of
bleeding was 650 mL.
During the 3 days after surgery, the patient was withdrawed
from the respirator. The hemoglobin level decreased to 7.7 g/dL
after surgery. Iron administration and 200 mL of intraoperative sal-
vaged blood transfusion were performed. The hemoglobin level
increased to 9.0 g/dL (Fig. 4). Postoperative complications included
aspiration pneumonia associated with left recurrent laryngeal nerve
paralysis and prolonged chylothorax. However, these improved
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with conservative treatment, and the patient was discharged on
the postoperative day 27.
Fig. 1 : Pretherapeutic findings.
Upper endoscopy on admission shows a tumor covering more than half of the upper thoracic esophagus, which made passage of the endoscope
difficult (a). Chest computed tomography (CT) on admission shows thickening of the esophageal wall in the upper (b) and lower (c) thoracic esophagus.
Fig. 2 : Post -chomotherapeutic findings.
Endoscopy shows the lesion in the upper esophagus was completely disappeared (a). CT shows marked reduction of the lesion both in the upper
(b) and lower (c) thoracic esophagus.
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DISCUSSION :
Jehovah’s Witnesses refuse blood infusion on religious grounds.
However, restrictions on use of blood products have variation.
When obtaining informed consent from patients who are Jehovah’s
Witnesses, the surgeon and anesthesiologist must sign an agree-
ment with the patient for the deed of indemnity. The surgeon also
must explain the need for preoperatively diluted and intraopera-
tively blood salvage and albumin preparations, describe the esti-
mated amount of bleeding to the patient and their family, and ob-
tain their consent (2, 3).
Therapeutic outcomes for Jehovah’s Witnesses including the
field of cardiovascular surgery (4) and liver transplant (5) were
reported. However, there is no fixed opinion regarding therapeutic
indications for Jehovah’s Witnesses with malignant tumors (6, 7).
Differences in the surgical procedure invasiveness, the disease
progression and concomitant anemia are considered to influence
the surgical indications. Preoperative blood-forming therapy and
autologous blood transfusions can be expand the treatment selec-
tion. Blood-forming therapy including iron and folic acid supple-
ments, vitamin B12, and erythropoietin was performed in our case.
Subtotal esophagectomy could be done safely with postoperative
autologous blood transfusions.
Autologous blood transfusion is classified broadly into (1) prede-
posit autologous donation (PAD), (2) acute normovolemic hemodi-
lution (ANH), and (3) perioperative cell salvage (PCS). PAD in-
volves collection of the patient’s blood in preparation for surgery.
But doctrine of Jehovah’s Witnesses cannot be accepted because
Fig. 3 : Transition of white blood cells and hemoglobin after starting of chemotherapy.
The patient was done blood- forming therapy. Two weeks prior to the surgery, the patient was intramuscular injection of erythropoietin (6000 U)
to increase her preoperative hemoglobin levels to 11.7 g/dL.
Fig. 4 : Transition of hemoglobin and albumin of postoperative.
The serum albumin was increased by albumin preparations. The hemoglobin level increased to 9.0 g/dL by injected iron and intraoperative blood
salvage.
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of collecting blood has been separated from the body. ANH is a
method in which autologous blood is collected prior to surgery
and diluted by supplementing decrease of circulating blood volume
using Ringer’s lactate and plasma substitutes. Because the blood
is dilution, actual blood loss can be suppressed. The collected
blood is physiologically superior in terms of hemostatic effect and
oxygen-carrying capacity and therefore has the advantage. PCS
is frequently used to reduce the amount allogeneic blood in car-
diovascular surgery (2). Similar to ANH, PCS is acceptable under
the doctrine of Jehovah’s Witnesses because blood is not separated
from the circulatory system. Various complications that occur dur-
ing PCS have been reported, including sepsis and distant metas-
tasis due to bacteria and cancer cells that are mixed within the
circuit (8). Autologous blood was not collected during dissection
of the T4 tumor of the lower esophagus, because tumor contami-
nation was expected. As for safety and long-term follow-up results
of cancer surgery, few clinical problems have reported (9-11).
We found two reports by searching the Japan Medical Abstracts
Society and PubMed databases using the keywords “Jehovah’s
Witness” and “esophagectomy” from 1994 to the present (12). Sub-
total esophagectomy had been performed in two cases of esopha-
geal cancer and the amount of intraoperative bleeding was approxi-
mately 800 mL in both the cases. In one case was used ANH alone
and in the other was used a combination of ANH and PCS, and no
intraoperative or postoperative problems occurred in both. Post-
operative complications were observed in several patients whose
amount of bleeding due to hepatectomy or pancreatectomy ex-
ceeded 2,000 mL, and some patients died after surgery (12). No
reports of esophageal resection following neoadjuvant chemother-
apy were found. But we found the reports of other cancers in which
anemia and thrombocytopenia were problems related to neoadju-
vant chemotherapy (13, 14). The patients in these reports also un-
derwent blood-forming therapy, and surgery was performed by
combining PCS with ANH.
Avoidance of blood transfusions of Jehovah’s Witnesses does
not mean that they accept death by refusing necessary treatments.
Physicians therefore need to treat these patients while respecting
their right to self -determination by applying any techniques that
do not involve blood transfusion. Blood transfusion and fresh fro-
zen plasma can be avoided by performing alternative therapies to
blood transfusions. We believe that treatments based on a blood
replacement therapy and autologous blood transfusions can widen
the range of surgical indications, including those for neoadjuvant
chemotherapy, in Jehovah’s Witnesses with gastrointestinal ma-
lignancies.
CONCLUSIONS :
We treated a Jehovah’s Witness with advanced esophageal
cancer who safely underwent subtotal esophagectomy following
to neoadjuvant chemotherapy. We could expand the therapeutic
indications of Jehovah’s Witnesses with gastrointestinal malignan-
cies by using blood replacement and autologous blood transfusion.
CONSENT :
Written informed consent was obtained from the patient for pub-
lication of this Case report and the accompanying images. A copy
of the written consent is available for review by the Editor of this
journal.
Abbreviations : PAD : predeposit autologous donation ; ANH :
acute normovolemic hemodilution ; PCS : perioperative cell salvage.
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